search
Back to results

Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703) (rEndosc)

Primary Purpose

Esophageal Varices in Cirrhosis of the Liver

Status
Withdrawn
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Endoscopy
CTA
Sponsored by
Nanfang Hospital, Southern Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Esophageal Varices in Cirrhosis of the Liver focused on measuring Esophageal Varices, Variceal Hemorrhage, Endoscopy, Radiomics, Hepatitis B Virus

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18-75 years;
  • HBsAg positive;
  • confirmed cirrhosis based on results of histologic examination of liver tissue or combined physical, laboratory, and radiologic findings, including a nodular surface, a coarse texture, and an enlarged caudate lobe of the liver on ultrasonography, CT, or MR imaging.

Exclusion Criteria:

  • active alcohol abuse (less than 6 months of alcohol abstinence); portal thrombosis;
  • history of treatments for portal hypertension (drug therapy, such as β-blocker, vasopressin) within 2 weeks;
  • prior surgeries (such as splenectomy, partial splenic embolization/devascularization, transjugular intrahepatic portosystemic shunt);
  • prior endoscopic therapies (such as endoscopic variceal ligation);
  • previous variceal hemorrhage;
  • acute-on-chronic (sub-acute) liver failure;
  • malignant tumor (such as hepatocellular carcinoma);
  • cirrhotic portal hypertension with isolated gastric varices or ectopic varices;
  • inability to adhere to study procedures (such as heart failure, renal failure);
  • pregnancy or unknown pregnancy status;
  • no informed consent.

Sites / Locations

  • 302 Hospital of PLA
  • Beijing Friendship Hospital, Capital Medical University
  • Beijing YouAn Hospital, Capital Medical University
  • Chinese PLA General Hospital
  • Peking University People's Hospital
  • The Second Affiliated Hospital of Chongqing Medical University
  • Nanfang Hospital, Southern Medical University
  • Xingtai People's Hospital
  • Shandong Provincial Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Single arm study

Arm Description

Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy

Outcomes

Primary Outcome Measures

Diagnostic Accuracy of rEndosc for Esophageal Varices
Diagnostic accuracy of rEndosc to determine the presence or absence of esophageal varices when compared to endoscopic examination as the reference standard

Secondary Outcome Measures

Diagnostic Accuracy of rEndosc for the Risk of Variceal Hemorrhage
Diagnostic accuracy of rEndosc to stratify risk of variceal hemorrhage when compared to endoscopic examination as the reference standard
Diagnostic Accuracy of rEndosc for Variceal Hemorrhage
Diagnostic accuracy of rEndosc to determine the presence or absence of variceal hemorrhage within 1-year follow-up

Full Information

First Posted
December 5, 2017
Last Updated
June 16, 2019
Sponsor
Nanfang Hospital, Southern Medical University
Collaborators
Beijing YouAn Hospital, Beijing 302 Hospital, Shandong Provincial Hospital, Beijing Friendship Hospital, The Second Affiliated Hospital of Chongqing Medical University, Chinese PLA General Hospital, Peking University People's Hospital, Xingtai People's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03373123
Brief Title
Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)
Acronym
rEndosc
Official Title
Radiomics-based Surrogate of Endoscopy (rEndosc) for Noninvasive Prediction of Esophageal Varices and Risk Stratification of Variceal Hemorrhage in Hepatitis B Virus-related Cirrhosis (CHESS1703)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Funding issue
Study Start Date
December 18, 2017 (Actual)
Primary Completion Date
December 18, 2018 (Anticipated)
Study Completion Date
December 18, 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nanfang Hospital, Southern Medical University
Collaborators
Beijing YouAn Hospital, Beijing 302 Hospital, Shandong Provincial Hospital, Beijing Friendship Hospital, The Second Affiliated Hospital of Chongqing Medical University, Chinese PLA General Hospital, Peking University People's Hospital, Xingtai People's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of cirrhosis with a high mortality when variceal hemorrhage (VH) occurs. Screening endoscopy for EVs is recommended for all patients with cirrhosis, and prophylactic treatments are proposed for preventing VH, which may be financially onerous. Therefore, noninvasive tools for diagnosing EVs and risk stratifying VH in cirrhotic patients are needed to decrease the number of unnecessary invasive endoscopic examinations of low-risk patients and avoid unneeded prophylactic treatment. This is a prospective, multi-center diagnostic trial conducted at 9 high-volume liver centers in China designed to determine the diagnostic performance of radiomics-based surrogate (rEndosc) (investigational technology) by CT imaging for noninvasive prediction of EVs and risk stratification of VH in patients with hepatitis B virus-related cirrhosis using endoscopic examinations as reference standard.
Detailed Description
Esophageal varices (EVs) resulting from portal hypertension are a prevalent complication of cirrhosis with a high mortality when variceal hemorrhage (VH) occurs. Screening endoscopy for EVs is recommended for all patients with cirrhosis, and prophylactic treatments are proposed for preventing VH, which may be financially onerous. Therefore, noninvasive tools for diagnosing EVs and risk stratifying VH in cirrhotic patients are needed to decrease the number of unnecessary invasive endoscopic examinations of low-risk patients and avoid unneeded prophylactic treatment. This is a prospective, multi-center diagnostic trial conducted at 9 high-volume liver centers (Beijing YouAn Hospital, Capital Medical University; Nanfang Hospital, Southern Medical University; 302 Hospital of PLA; Shandong Provincial Hospital; Beijing Friendship Hospital, Capital Medical University; Chinese PLA General Hospital; Peking University People's Hospital; Xingtai People's Hospital) in China designed to determine the diagnostic performance of radiomics-based surrogate (rEndosc) (investigational technology) by CT imaging for noninvasive prediction of EVs and risk stratification of VH in patients with hepatitis B virus-related cirrhosis using endoscopic examinations as reference standard.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Varices in Cirrhosis of the Liver
Keywords
Esophageal Varices, Variceal Hemorrhage, Endoscopy, Radiomics, Hepatitis B Virus

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single arm study
Arm Type
Experimental
Arm Description
Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
Intervention Type
Procedure
Intervention Name(s)
Endoscopy
Intervention Description
Endoscopy
Intervention Type
Procedure
Intervention Name(s)
CTA
Intervention Description
Radiomic features were extracted from CTA images.
Primary Outcome Measure Information:
Title
Diagnostic Accuracy of rEndosc for Esophageal Varices
Description
Diagnostic accuracy of rEndosc to determine the presence or absence of esophageal varices when compared to endoscopic examination as the reference standard
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Diagnostic Accuracy of rEndosc for the Risk of Variceal Hemorrhage
Description
Diagnostic accuracy of rEndosc to stratify risk of variceal hemorrhage when compared to endoscopic examination as the reference standard
Time Frame
1 day
Title
Diagnostic Accuracy of rEndosc for Variceal Hemorrhage
Description
Diagnostic accuracy of rEndosc to determine the presence or absence of variceal hemorrhage within 1-year follow-up
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18-75 years; HBsAg positive; confirmed cirrhosis based on results of histologic examination of liver tissue or combined physical, laboratory, and radiologic findings, including a nodular surface, a coarse texture, and an enlarged caudate lobe of the liver on ultrasonography, CT, or MR imaging. Exclusion Criteria: active alcohol abuse (less than 6 months of alcohol abstinence); portal thrombosis; history of treatments for portal hypertension (drug therapy, such as β-blocker, vasopressin) within 2 weeks; prior surgeries (such as splenectomy, partial splenic embolization/devascularization, transjugular intrahepatic portosystemic shunt); prior endoscopic therapies (such as endoscopic variceal ligation); previous variceal hemorrhage; acute-on-chronic (sub-acute) liver failure; malignant tumor (such as hepatocellular carcinoma); cirrhotic portal hypertension with isolated gastric varices or ectopic varices; inability to adhere to study procedures (such as heart failure, renal failure); pregnancy or unknown pregnancy status; no informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huiguo Ding, M.D.
Organizational Affiliation
Beijing YouAn Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiaolong Qi, M.D.
Organizational Affiliation
Nanfang Hospital, Southern Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
302 Hospital of PLA
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Beijing Friendship Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Beijing YouAn Hospital, Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
Peking University People's Hospital
City
Beijing
State/Province
Beijing
Country
China
Facility Name
The Second Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Facility Name
Nanfang Hospital, Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Facility Name
Xingtai People's Hospital
City
Xingtai
State/Province
Hebei
Country
China
Facility Name
Shandong Provincial Hospital
City
Jinan
State/Province
Shandong
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27786365
Citation
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1. No abstract available. Erratum In: Hepatology. 2017 Jul;66(1):304.
Results Reference
background
PubMed Identifier
26047908
Citation
de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3. No abstract available.
Results Reference
background
PubMed Identifier
26579733
Citation
Gillies RJ, Kinahan PE, Hricak H. Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2016 Feb;278(2):563-77. doi: 10.1148/radiol.2015151169. Epub 2015 Nov 18.
Results Reference
background
PubMed Identifier
17515910
Citation
Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, Chen X, Chan BK, Matcuk GR, Barry CT, Chang HY, Kuo MD. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007 Jun;25(6):675-80. doi: 10.1038/nbt1306. Epub 2007 May 21.
Results Reference
background
PubMed Identifier
28975929
Citation
Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017 Dec;14(12):749-762. doi: 10.1038/nrclinonc.2017.141. Epub 2017 Oct 4.
Results Reference
background
PubMed Identifier
27138577
Citation
Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, Ma ZL, Liu ZY. Development and Validation of a Radiomics Nomogram for Preoperative Prediction of Lymph Node Metastasis in Colorectal Cancer. J Clin Oncol. 2016 Jun 20;34(18):2157-64. doi: 10.1200/JCO.2015.65.9128. Epub 2016 May 2. Erratum In: J Clin Oncol. 2016 Jul 10;34(20):2436.
Results Reference
background

Learn more about this trial

Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)

We'll reach out to this number within 24 hrs